KINETIC-TECHNOLOGIES
15.11.2022 07:01:41 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced two new milestone products that can increase the Power Delivery capability of USB Type-C ports to 140W, removing the barrier to expanding the range of electronic products charged via USB. The KTS1898 is dedicated to switching and protecting VBUS power, while the KTU1128 is dedicated to switching and protecting the CC1/2 and SBU1/2 lines.
The KTS1898 is a low-resistance, 5A load switch with soft-start, overvoltage, “ideal diode” reverse-current, short-circuit, over-current, over-temperature and ESD protection plus integrated surge protection of ±100V, designed to isolate and protect downstream components from abnormal VBUS voltage and current conditions. The fast reverse current protection (ideal diode) allows multiple power paths to be connected to VBUS OUT without interference.
The KTU1128 companion IC is a Thunderbolt compatible, Type-C USB data line protection and switch IC, providing low-resistance, ultra-fast OVP, and surge protection for the CC and SBU lines. Maintaining pin-to-pin compatibility with existing products, the KTU1128 increases the operating tolerance on CC and SBU lines to 32V for short-to-VBUS protection and reduces the quiescent current.
“The KTS1898 and KTU1128 are industry leading devices that allow designers to implement USB Type-C PD3.1 Extended Power Range (EPR) up to 140W and effectively address safety at the same time,” says Erik Ogren, Kinetic Technologies Senior Director of Marketing. “With the ability to withstand up to +35V on VBUS, the KTS1898 delivers the margin our customers require to build 28V systems that are designed to be safe and reliable, while the super low-resistance 25mΩ MOSFET keeps heat to a minimum, which is essential when operating at such high-power levels. The KTU1128 features the same built-in robust protection and together extends Kinetic’s lead in this application.”
KTS1898 and KTU1128 samples are available now with production starting in first quarter 2023. Visit Kinetic Technologies for further information.
Key Product Highlights:
KTS1898 – 28V VBUS Protection
-
3V to 32V Operating Voltage Range
- 35V Abs Max. Rating at IN & OUT
-
5A Continuous Current Rating
- 10A peak
- Supports 140W USB Power Delivery 3.1 (EPR)
- “Ideal Diode” Reverse-current protection with 15µs fast recovery
- Full Protection: OVP, SCP, OCP, OTP & RCP
- IEC61000-4-5 Surge Protection ±100V
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
KTU1128 – 28V CC/SBU Protection
-
2.5V to 5.5V Operating Voltage Range
- 32V DC Tolerance on CC1/2, SBU1/2
- Thunderbolt Compatible
- Fast 70ns OVP response time
- IEC61000-4-5 Surge Protection ±40V/±30V CC/SBU
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom